The role of macrophages in antitumor defense of patients with ovarian cancer

Hematology/Oncology Clinics of North America

Volumn 13, Issue 1, 1999, Pages 135-144

  Zavadova, E ^a   Loercher, A ^a   Verstovsek, S ^a   Verschraegen, C F ^a   Micksche, M ^a   Freedman, R S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE ACTIVATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ASCITES; CYTOKINE RELEASE; CYTOTOXICITY; HOST RESISTANCE; HUMAN; MACROPHAGE; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 0033004230     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70157-X     Document Type: Article

References (48)

1. D.O. Adams T.A. Hamilton The cell biology of macrophage activation Annu Rev Immunol 2 1984 283
2. P. Allavena M. Grandi M. D'Incalci Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes Int J Cancer 40 1987 104
3. R. Andreesen Macrophage-directed tumor immunotherapy revisited—Past and future of an old doctor's dilemma Res Immunol 144 1993 291
4. M.J. Auger Mononuclear phagocytes BMJ 298 1989 546
5. S. Bernasconi C. Matteucci M. Sironi Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages Int J Cancer 60 1995 300
6. C. Bogdan C. Nathan Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10 Ann N Y Acad Sci 685 1993 713
7. I.L. Bonta S. Ben-Efraim Involvement of inflammatory mediators in macrophage antitumor activity J Leukoc Biol 54 1993 613
8. C. Bucana L.C. Hoyer B. Hobbs Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells Cancer Res 36 1976 4444
9. C. Buelens F. Willems G. Pierard IL-10 inhibits the primary allogeneic T-cell response to human peripheral blood dendritic cells Adv Exp Med Biol 378 1995 363
10. R.M. Bukowski S. Murthy D. McLain Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: Clinical and immunologic effects J Immunother Emphasis Tumor Immunol 13 1993 267
11. S. Chouaib C. Asselin-Paturel F. Mami-Choabib The host tumor immune conflict: From immunosuppression to resistance and destruction Immunol Today 18 1997 493
12. G.J. Dougherty W.H. McBride Macrophage heterogeneity J Clin Lab Immunol 14 1984 1
13. B.E. Drysdale S. Agarwal H.S. Shin Macrophage-mediated tumoricidal activity: Mechanisms of activation and cytotoxicity Progress in Allergy 40 1988 111
14. H.F. Dvorak Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing New Engl J Med 315 1986 1650
15. J.S. Econmou S.D. Colquhoun T.M. Anderson Interleukin-1 and tumor necrosis factor production by tumor-associated mononuclear leukocytes and peripheral mononuclear leukocytes in cancer patients Int J Cancer 42 1988 712
16. A. Erroi M. Sironi F. Chiaffarino IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma Int J Cancer 44 1989 795
17. R.S. Freedman J.A. Gibbons M. Giedlin Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma J Immunother Emphasis Tumor Immunol 19 1996 443
18. H. Goey J.R. Keller T. Back Inhibition of early murine hematopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1 J Immunol 143 1989 877
19. R. Hafter W. Klaubert R. Gollwitzer Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis Thromb Res 35 1984 53
20. D.J. Herzyk A.E. Berger J.N. Allen Sandwich ELISA formats designed to detect 17 kDa IL-1 beta significantly underestimate 35 kDa IL-1 beta J Immunol Methods 148 1992 243
21. M. Higuchi N. Higashi H. Taki Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and l -arginine–dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages J Immunol Emphasis Tumor Immunol 144 1990 1425
22. H. Hirte D.A. Clark Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-beta as a suppressive factor Cancer Immunol Immunother 32 1991 296
23. R. Jänicke D.N. Männel Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis J Immunol 144 1990 1144
24. Johnston R.B. Jr Current concepts: Immunology. Monocytes and macrophages N Engl J Med 318 1988 747
25. J. Klostergaard Role of tumor necrosis factor in monocyte/macrophage tumor cytotoxicity in vitro Natural Immunity & Cell Growth Regulation 6 1987 161
26. H. Koelbl M. Micksche G. Gitsch Treatment with biologic response modifiers in patients with ovarian cancer Eur J Obstet Gynaecol Reprod Biol 41 1991 64
27. Loercher AE, Nash MA, Platsoucas CD, et al: IL-10–producing monocytes in malignant ascites from ovarian cancer patients [abstract 1078]. In Proceedings of the 89th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 1998
28. A. Mantovani Tumor-associated macrophages Curr Opin Immunol 2 1990 689
29. A. Mantovani B. Bottazzi F. Colotta The origin and function of tumor-associated macrophages Immunol Today 13 1992 265
30. A. Mantovani W.J. Ming C. Balotta Origin and regulation of tumor-associated macrophages: The role of tumor-derived chemotactic factor Biochim Biophys Acta 865 1986 59
31. E.F. McClay P.D. Braly S. Kirmani A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies Cancer 74 1994 664
32. M.S. Meltzer R.W. Tucker A.C. Breuer Interaction of BCG-activated macrophages with neoplastic and nonneoplastic cell lines in vitro: Cinemicrographic analysis Cell Immunol 17 1975 30
33. M. Micksche Interferon–ein neues therapeutisches Prinzip Wiener Medizinische Wochenschrif 143 1993 408
34. M. Micksche Neue Aspekte der Interferontherapie bei malignen Erkrankungen Wiener Medizinische Wochenschrif 143 1993 454
35. M.A. Nash C.L. Edwards J.J. Kavanagh Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumor specimens, peritoneal exudate cells containing tumor, TIL-derived T-cell lines, and established tumor cell lines Clin Exp Immunol 112 1998 172
36. C.F. Nathan Secretory products of macrophages J Clin Invest 79 1987 319
37. A. Nii I.J. Fidler The incubation of human blood monocytes with tumor necrosis factor alpha leads to lysis of tumor necrosis factor–sensitive but not resistant tumor cells Lymphokine Research 9 1990 113
38. J.A. O'Shaughnessy A. Tolcher D. Riseberg Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer Blood 87 1996 2205
39. K.R. Prowse H. Baumann Interleukin-1 and interleukin-6 stimulate acute-phase protein production in primary mouse hepatocytes J Leukoc Biol 45 1989 55
40. E. Pujade-Lauraine J.P. Guastalla N. Colombo Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy J Clin Oncol 14 1996 343
41. A.K. Roska P.E. Lipsky Monocytes and macrophages Kelley W.N. Harris E.D. Jr Ruddy S. Textbook of Rheumatology 3 ed 1989 WB Saunders Philadelphia 349
42. J. Schuller M.J. Czejka G. Schernthaner Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administration Semin Oncol 19 2 Suppl 3 1992 98
43. C.F. Verschraegen A.P. Kudelka W. Termrungruanglert Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease Eur J Cancer 32A 1996 1609
44. Z. Werb Phagocytic cells Stites D.P. J.D. Stobo J.V. Wells Basic and Clinical Immunology 6 ed 1987 Appleton & Lange Norwalk, CT 96
45. P.W. Whitworth C.C. Pak J. Esgro Macrophages and cancer Cancer Metastasis Rev 8 1990 319
46. E. Zavadova E. Pedram E. Hauptmann Activation of human malignant effusion-derived macrophages by cytokines and a polyenzyme preparation European Journal of Infectious Immunology 1 1996 45
47. E. Zavadova E. Pedram E. Hauptmann GM-CSF and interferon-γ modulate cytotoxicity and cytokine production of malignant effusion-derived macrophages Eur J Cancer 32A 1996 l1
48. E. Zavadova E. Pedram E. Hauptmann Modulation of human malignant effusion-derived macrophages by cytokines and a polyenzyme preparation Proceedings of the American Association of Cancer Research 39 1998 155